Objective: To evaluate the bioequivalence of two preparations of allopurinol tablets. Methods: Serum concentrations of allopurinol were measured by RP-HPLC. 300mg single oral allopurinol tablets were given to 20 healthy human subjects in an open randomized crossover way to study the pharmacokinetics and bioequivalence. Results: The AUC0~8
cmax
tmax and t1/2 of brands A and B were (8.02±2.08) g·h/ml and (8.12±2.07)g·h/ml
(2.77±0.83) g/ml and (2.73±0.84) g/ml
(1.22±0.40)h and (1.27±0.33)h
(1.79±0.77)h and (1.83±0.99)h
respectively. The mean relative bioavailability of brand A vs brand B was 98.77%±13.09%. Conclusion: The two formulations were bioequivalent.